EGFR and non-small cell lung carcinoma: Given the high percentage of NSCLC being diagnosed in the advanced stage with a poor survival outcome, EGFR inhibition alone or combined with other approaches in the treatment of NSCLC become a very attractive strategy which has been validated in pre-clinical and preliminary clinical trials [12-14].